Glycemic-aware metrics and oversampling techniques for predicting blood glucose levels using machine learning.
Blood Glucose
/ analysis
Blood Glucose Self-Monitoring
/ instrumentation
Datasets as Topic
Diabetes Mellitus, Type 1
/ blood
Forecasting
Humans
Hypoglycemia
/ blood
Hypoglycemic Agents
/ administration & dosage
Insulin
/ administration & dosage
Laboratory Critical Values
Pancreas, Artificial
Self Medication
/ adverse effects
Support Vector Machine
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
29
07
2019
accepted:
07
11
2019
entrez:
3
12
2019
pubmed:
4
12
2019
medline:
27
3
2020
Statut:
epublish
Résumé
Techniques using machine learning for short term blood glucose level prediction in patients with Type 1 Diabetes are investigated. This problem is significant for the development of effective artificial pancreas technology so accurate alerts (e.g. hypoglycemia alarms) and other forecasts can be generated. It is shown that two factors must be considered when selecting the best machine learning technique for blood glucose level regression: (i) the regression model performance metrics being used to select the model, and (ii) the preprocessing techniques required to account for the imbalanced time spent by patients in different portions of the glycemic range. Using standard benchmark data, it is demonstrated that different regression model/preprocessing technique combinations exhibit different accuracies depending on the glycemic subrange under consideration. Therefore technique selection depends on the type of alert required. Specific findings are that a linear Support Vector Regression-based model, trained with normal as well as polynomial features, is best for blood glucose level forecasting in the normal and hyperglycemic ranges while a Multilayer Perceptron trained on oversampled data is ideal for predictions in the hypoglycemic range.
Identifiants
pubmed: 31790464
doi: 10.1371/journal.pone.0225613
pii: PONE-D-19-21382
pmc: PMC6886807
doi:
Substances chimiques
Blood Glucose
0
Hypoglycemic Agents
0
Insulin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0225613Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Diabetes Care. 1987 Sep-Oct;10(5):622-8
pubmed: 3677983
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Bioelectron Med. 2018 Nov 7;4:14
pubmed: 32232090
Diabetes Technol Ther. 2018 May;20(5):353-362
pubmed: 29688755
Diabetes Technol Ther. 2017 Mar;19(3):155-163
pubmed: 28134564
Artif Intell Med. 2019 Jul;98:109-134
pubmed: 31383477
Diabetes Obes Metab. 2015 May;17(5):468-76
pubmed: 25600304
Diabetes Care. 2017 Dec;40(12):1631-1640
pubmed: 29162583
JAMA. 2017 Jan 24;317(4):379-387
pubmed: 28118454
Sensors (Basel). 2017 Aug 12;17(8):
pubmed: 28805693
Int J Numer Method Biomed Eng. 2017 Jun;33(6):
pubmed: 27644067
Diabetes Care. 2015 Jun;38(6):971-8
pubmed: 25998289
Neural Comput. 2000 May;12(5):1207-45
pubmed: 10905814
Lancet. 2018 Jun 16;391(10138):2449-2462
pubmed: 29916386
Diabetes Care. 2018 Feb;41(2):303-310
pubmed: 29191844